SRR12202497
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.330
- PEROXISOME+0.260
- E2F_TARGETS+0.220
- BILE_ACID_METABOLISM+0.200
- G2M_CHECKPOINT+0.160
- DNA_REPAIR+0.150
- SPERMATOGENESIS+0.150
- CHOLESTEROL_HOMEOSTASIS+0.110
- MYC_TARGETS_V2+0.110
- XENOBIOTIC_METABOLISM+0.110
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.650
- INTERFERON_GAMMA_RESPONSE-0.560
- IL6_JAK_STAT3_SIGNALING-0.510
- ANGIOGENESIS-0.500
- ALLOGRAFT_REJECTION-0.480
- INFLAMMATORY_RESPONSE-0.480
- TGF_BETA_SIGNALING-0.430
- TNFA_SIGNALING_VIA_NFKB-0.430
- KRAS_SIGNALING_UP-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GV-A40G-01A-11R-A23N-07 | — | — | 0.909 |
| 2 | 80680b8f-eec8-4b02-95c4-f133af61943a | — | — | 0.902 |
| 3 | SRR1516068 | — | — | 0.901 |
| 4 | SRR1516065 | — | — | 0.892 |
| 5 | TCGA-XF-A8HC-01A-11R-A36F-07 | — | — | 0.878 |
| 6 | TCGA-55-8620-01A-11R-2403-07 | — | cohortA3 | 0.875 |
| 7 | SRR8943043 | — | — | 0.872 |
| 8 | R55 | — | — | 0.871 |
| 9 | SRR8943037 | — | — | 0.871 |
| 10 | TCGA-GV-A3JW-01A-11R-A20F-07 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| PEROXISOME | 0.260 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |